EA201590053A1 - Модуляторы пути системы комплемента и их применение - Google Patents

Модуляторы пути системы комплемента и их применение

Info

Publication number
EA201590053A1
EA201590053A1 EA201590053A EA201590053A EA201590053A1 EA 201590053 A1 EA201590053 A1 EA 201590053A1 EA 201590053 A EA201590053 A EA 201590053A EA 201590053 A EA201590053 A EA 201590053A EA 201590053 A1 EA201590053 A1 EA 201590053A1
Authority
EA
Eurasian Patent Office
Prior art keywords
complement system
modulators
application
inhibitor
compound
Prior art date
Application number
EA201590053A
Other languages
English (en)
Inventor
Михаэль А. Дечантсрайтер
Джонатан Э. Гроб
Аенгус Мак Свини
Вольфганг Мильтц
Штефан Рандль
Рихард Седрани
Хольгер Зелльнер
Финтон Сирокин
Эрик Валер
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201590053A1 publication Critical patent/EA201590053A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Настоящее изобретение относится к соединению формулы Iспособу получения соединения по изобретению и его терапевтическому применению в качестве ингибитораальтернативного пути системы комплемента и, в частности, в качестве ингибитора фактора В для лечения возрастной дегенерации желтого пятна и диабетической ретинопатии. Настоящее изобретение дополнительно относится к комбинации фармакологически активных средств и фармацевтической композиции.
EA201590053A 2012-06-20 2013-06-19 Модуляторы пути системы комплемента и их применение EA201590053A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261662002P 2012-06-20 2012-06-20
US201361776244P 2013-03-11 2013-03-11
PCT/US2013/046644 WO2013192345A1 (en) 2012-06-20 2013-06-19 Complement pathway modulators and uses thereof

Publications (1)

Publication Number Publication Date
EA201590053A1 true EA201590053A1 (ru) 2015-08-31

Family

ID=48741572

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590053A EA201590053A1 (ru) 2012-06-20 2013-06-19 Модуляторы пути системы комплемента и их применение

Country Status (12)

Country Link
US (1) US9452990B2 (ru)
EP (1) EP2864322B1 (ru)
JP (1) JP6163205B2 (ru)
KR (1) KR20150033652A (ru)
CN (1) CN104662015B (ru)
AU (1) AU2013277154A1 (ru)
BR (1) BR112014031375A2 (ru)
CA (1) CA2877526A1 (ru)
EA (1) EA201590053A1 (ru)
ES (1) ES2584702T3 (ru)
MX (1) MX2014015933A (ru)
WO (1) WO2013192345A1 (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010075257A1 (en) 2008-12-22 2010-07-01 Chemocentryx, Inc. C5ar antagonists
PL2585064T3 (pl) 2010-06-24 2017-09-29 Chemocentryx, Inc. Antagoniści C5AR
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
JP6616786B2 (ja) * 2014-05-19 2019-12-04 メリアル インコーポレイテッド 駆虫性化合物
CN113121415A (zh) 2014-09-29 2021-07-16 凯莫森特里克斯股份有限公司 制备C5aR拮抗剂的方法和中间体
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
CN106632091B (zh) * 2015-10-29 2021-05-11 中国科学院上海药物研究所 喹唑啉化合物在调控神经干细胞增殖和分化中的应用
BR112018014222A2 (pt) * 2016-01-14 2018-12-11 Chemocentryx, Inc. método de tratamento da glomerulopatia c3
WO2018005552A1 (en) * 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
CN106854161B (zh) * 2016-12-30 2019-01-11 重庆医科大学 3,4-二甲氧基-6-硝基苯甲酸的合成方法
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
AU2018227849B2 (en) 2017-03-01 2022-04-28 Achillion Pharmaceuticals, Inc. Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
WO2020041301A1 (en) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
KR20210057086A (ko) 2018-09-06 2021-05-20 아칠리온 파르마세우티칼스 인코포레이티드 다니코판의 형태체 형태
CN112996497A (zh) 2018-09-25 2021-06-18 艾其林医药公司 补体因子d抑制剂的形态形式
WO2022028527A1 (zh) 2020-08-07 2022-02-10 上海美悦生物科技发展有限公司 补体因子b抑制剂及其药物组合物、制备方法和用途
US20230331710A1 (en) 2020-08-07 2023-10-19 Shanghai Meiyue Biotech Development Co. Ltd Heterocyclic compound, preparation method and use thereof
CN112778162B (zh) * 2021-01-06 2023-06-16 上海海皋科技有限公司 一种手性β-(Boc-氨基)-5-己炔酸的制备方法
CA3224591A1 (en) * 2021-07-02 2023-01-05 Yuhua Li Methods of manufacturing injectable sustained release formulations

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5466691A (en) 1977-11-08 1979-05-29 Mitsubishi Yuka Yakuhin Kk Novel quinazoline derivative and manufacture
GB2068961B (en) 1980-02-13 1983-11-30 Sankyo Co Quinazoline derivatives
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4656174A (en) 1982-07-24 1987-04-07 Pfizer Inc. Quinoline therapeutic agents
JP2852659B2 (ja) 1988-03-03 1999-02-03 富山化学工業株式会社 ピペラジン誘導体およびその塩
RU2124511C1 (ru) 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
IT1270993B (it) 1994-03-18 1997-05-26 Recordati Chem Pharm Derivati chinzolilamminici attivi come alfa-antagonisti
US5599809A (en) 1994-09-29 1997-02-04 Merck & Co., Inc. Method for improving reproductive efficiency in farm animals
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
WO1997020820A1 (en) 1995-12-01 1997-06-12 Novartis Ag Heteroaryl compounds
JPH107572A (ja) 1996-06-17 1998-01-13 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
AU2793199A (en) 1998-02-26 1999-09-15 Neurogen Corporation 2-(het-)aryl-4-(cyclic amino substituted) heteroaryl fused pyridine derivatives,their preparation and their use as (ant-)agonists for gaba (a) brain receptors
US6376496B1 (en) 1999-03-03 2002-04-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JP2000281660A (ja) * 1999-03-29 2000-10-10 Sumitomo Pharmaceut Co Ltd キナゾリン誘導体
US6642228B1 (en) 1999-06-24 2003-11-04 Toray Industries, Inc. α1b-adrenergic receptor antagonists
US20020025967A1 (en) 1999-12-16 2002-02-28 Smith Miles P. N-alkylpiperdine analogs and uses thereof in treating addictions
WO2001062750A1 (en) 2000-02-21 2001-08-30 Astrazeneca Ab Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
AU2001240150A1 (en) 2000-03-13 2001-09-24 Chemrx Advanced Technologies, Inc. Quinazoline synthesis
US6723730B2 (en) 2000-07-20 2004-04-20 Neurogen Corporation Capsaicin receptor ligands
US6949655B2 (en) 2001-06-14 2005-09-27 David Lauffer Acyclic piperidine derivatives
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
WO2004002960A1 (en) 2002-06-27 2004-01-08 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
WO2004010942A2 (en) 2002-07-31 2004-02-05 Smithkline Beecham Corporation Substituted heterocyclic compounds as modulators of the ccr5 receptor
WO2005005397A1 (en) 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag 5-substituted quinazolinone derivatives
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
RU2006121990A (ru) 2003-11-21 2007-12-27 Эррэй Биофарма Инк. (Us) Ингибиторы протеинкиназ акт
TW200524601A (en) 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
WO2005056524A2 (en) 2003-12-09 2005-06-23 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7820673B2 (en) 2003-12-17 2010-10-26 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
US20060264442A1 (en) * 2005-05-18 2006-11-23 Allergan, Inc. Methods for the treatment of ocular and neurodegenerative conditions in a mammal
MX2007016545A (es) 2005-06-30 2008-02-21 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
ES2625378T3 (es) 2005-09-27 2017-07-19 Shionogi & Co., Ltd. Derivado de sulfonamida que tiene actividad antagonista del receptor de PGD2
KR20180002911A (ko) * 2005-11-04 2018-01-08 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
US20080059907A1 (en) 2006-09-01 2008-03-06 Kari Jakobsson Saving the contents of the track list as a playlist file
CL2008001002A1 (es) 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
ES2379848T3 (es) 2007-05-14 2012-05-04 Sk Biopharmaceuticals Co., Ltd. Compuesto arilpiperazina arilalcanoil carbomoiloxi novedoso, composiciones farmacéuticas que comprenden el compuesto y método para tratar el dolor, ansiedad y depresión al administrar el compuesto
EP2170847A2 (en) 2007-06-28 2010-04-07 Intervet International BV Substituted piperazines as cb1 antagonists
TWI450720B (zh) 2007-07-05 2014-09-01 Array Biopharma Inc 作為ａｋｔ蛋白質激酶抑制劑之嘧啶環戊烷
EP2025678A1 (en) * 2007-08-17 2009-02-18 Oncalis AG Pyrazolo[3,4-d]pyrimidine compounds and their use as modulators of protein kinase
EP2133334A1 (en) 2008-06-09 2009-12-16 DAC S.r.l. Heterocyclic derivatives as HDAC inhibitors
CN102574857B (zh) * 2009-07-08 2015-06-10 利奥制药有限公司 作为jak受体和蛋白酪氨酸激酶抑制剂的杂环化合物

Also Published As

Publication number Publication date
CA2877526A1 (en) 2013-12-27
BR112014031375A2 (pt) 2017-06-27
CN104662015B (zh) 2017-03-29
US9452990B2 (en) 2016-09-27
MX2014015933A (es) 2015-07-17
AU2013277154A1 (en) 2014-12-18
JP6163205B2 (ja) 2017-07-12
US20150126492A1 (en) 2015-05-07
KR20150033652A (ko) 2015-04-01
EP2864322B1 (en) 2016-04-27
WO2013192345A1 (en) 2013-12-27
JP2015521624A (ja) 2015-07-30
ES2584702T3 (es) 2016-09-28
CN104662015A (zh) 2015-05-27
EP2864322A1 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
EA201590200A1 (ru) Модуляторы пути активации комплемента и их применение
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
ECSP14013217A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk.
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201391561A1 (ru) Новые соединения-модуляторы gpr-119
EA201490320A1 (ru) Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
BR112015010360A8 (pt) antagonistas de il-6 e utilização dos mesmos.
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201391000A1 (ru) Индольные соединения или их аналоги, полезные для лечения возрастной макулярной дегенерации (amd)
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
EA201490721A1 (ru) Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы
UA114001C2 (xx) Оксазолідин-2-он-піримідинові похідні
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
EA201490573A1 (ru) Соединение бензотиазолона